Abstract: Differential methylation profiles of a panel of genes are identified from colorectal carcinoma tissues of colorectal cancer patients compared to normal colon mucosal tissue or to white blood cells from healthy subjects. A high methylation level of cytosines at CpG dinucleotide sites (in CpG-rich regions) of the panel of genetic loci are further validated in plasma cell-free DNA as signature markers indicative of colorectal cancer, which is useful for early stage detection of colorectal cancer and monitoring of disease progression. This panel of genetic loci include genes MAP3K14-AS1, DNM1P46, EMBP1, GATM, VSV2, LAYN, and SFMBT2, which individually or in combination can complement SEPT9-based assays in improving sensitivity and/or specificity in the detection of colorectal cancer. Assay methods and reagents for detection of the presence and levels of methylation of the marker genetic loci are also provided.

Abstract: We describe a new genomic signature (MEN1 mut/DAXX wt) that correlates with PNET response to CAPTEM therapy. MEN1-mut/DAXX-wt status correlates with longer progression-free survival on CAPTEM in patients with pancreatic neuroendocrine tumors, relative to patients with MEN1-wt or DAXX-mut.

Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.

Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.

Abstract: The present invention provides for methods of treating solid tumors, particularly, KRas mutated solid tumors and KRas mutated pancreatic cancer. The method includes administering glutamine alone or in combination with an anti-cancer agent; for example, gemcitabine or nab-paclitaxel. The method includes administering glutamine and radiotherapy, or glutamine and immunotherapy to treat these cancers.

Abstract: The present invention provides for a method to treat pancreatic cancer. In various embodiments the method provides for administering one or more MAPK one or more MAPK pathway inhibitors to the subject, wherein the subject has a mutation in one or more genes in the MAPK signaling pathway.

Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.

Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.

Abstract: A composition for IL-1 inhibition in combination with cancer therapies (e.g., chemotherapeutics including chemotherapy protective drugs) is provided for use in treating pancreatic cancer cachexia in patients, so as to reduce weight loss and improve the quality of life and survival of the patients. In one embodiment, the IL-1 inhibitor is an antibody, such as bermekimab, anakinra, canakinumab, gevokizumab, or rilonacept, administered simultaneously or sequentially with iritenocan, 5-fluorouracil and folinic acid to a pancreatic cancer patient.